Posted by Michael Wonder on 18 Dec 2020
Sandoz Canada receives authorisation from Health Canada to launch new biosimilar Hyrimoz (adalimumab)
17 December 2020 - Hyrimoz approved for use in all same indications as reference medicine* including rheumatology, gastro-enterology and dermatology.
Sandoz Canada announced today that Health Canada has authorised Hyrimoz (adalimumab injection, reference biologic drug: Humira) on 4 November 2020 for marketing in Canada.
Hyrimoz has been approved for the treatment of the same nine life-threatening or serious debilitating conditions in adults and children as the reference medicine, including the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, psoriasis and adult uveitis.
